A Study of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia

Korábbi kezelés

• Patients who have received PCSK9i monoclonal antibody treatment in the last 3 months before the start of the triple therapy exposure
• Patients who have ever received PCSK9i-siRNA treatment

• Written informed consent to participate
• At least 18 years of age
• High and very high risk patients as assessed by the physician suffering from documented primary hypercholesterolemia or mixed dyslipidemia at start of bempedoic acid treatment
• Patients treated with:
  • bempedoic acid added to ezetimibe and rosuvastatin or atorvastatin,
  • bempedoic acid plus ezetimibe added to rosuvastatin or atorvastatin,
  • bempedoic acid plus atorvastatin or rosuvastatin added to ezetimibe
  • initiation of bempedoic acid, ezetimibe, and atorvastatin or rosuvastatin simultaneously
• Initiation of triple therapy within a maximum of four weeks prior to inclusion 7) An untreated LDL-C value must be available within 5 years prior to the start of the triple therapy. Untreated means that the LDL-C value is not influenced by any lipid lowering therapy at the time of blood collection. Time window for not being treated as specified in the protocol.
• No contraindications exist according to the SmPC of bempedoic acid, the respective statin and ezetimibe as per physicians' assessment 9) No concurrent participation in an interventional study (simultaneous participation in other non-interventional studies is possible) 10) Life expectancy > 1 -year